Since there are currently no US Food and Drug Administration (FDA)-approved drugs for the treatment of non-alcoholic steatohepatitis (NASH), various NASH treatments are under development for a wide range of targets. Several promising agents have recently failed in phase 3 trials, including selosertib [1], elafibranor, and cenicriviroc [2], and now five pharmacologic agents—obeticholic acid (OCA), resmetirom, aramchol, lanifibranor, and semaglutide—are being evaluated in large, histology-based phase 3 trials (Table 1).
Table 1.
Clinical trials evaluating the efficacy of various agents for nonalcoholic steatohepatitis
| Drug | Mechanism | Phase | Trial | Fibrosis stage | Size (n) | Current status |
|---|---|---|---|---|---|---|
| Obeticholic acid | FXR agonist | 3 | REGENERATE (NCT02548351) | NASH fibrosis (F1-3) | 2,480 | Active, not recruiting |
| FDA rejected the new drug application of OCA for pre-cirrhotic NASH | ||||||
| Resmetirom | Selective THR-β agonist | 3 | MAESTRO-NASH (NCT03900429) | NASH fibrosis (F2-3) | 2,000 | Ongoing |
| Semaglutide | GLP-1 RA | 3 | ESSENCE (NCT04822181) | NASH fibrosis (F2-3) | 1,200 | Ongoing |
| Dapagliflozin | SGLT2 inhibitor | 3 | DEAN (NCT03723252) | NASH | 100 | Ongoing |
| Aramchol | SCD1 inhibitor | 3 | ARMOR (NCT04104321) | NASH fibrosis (F2-3) | 2,000 | Part I (open-label) met its objective |
| Part II (double-blind) was suspended | ||||||
| Lanifibranor | Pan-PPAR agonist | 3 | NATiV3 (NCT04849728) | NASH fibrosis (F2-3) | 2,000 | Ongoing |
| Pegozafermin | FGF21 agonist | 2 | ENLIVEN (NCT04929483) | NASH fibrosis (F2-3) | 222 | Completed |
| Fibrosis significantly improved ≥1 stage without worsening of NASH |
FDA, US Food and Drug Administration; OCA, obeticholic acid; GIP, glucose-dependent insulinotropic polypeptide; GLP-1 RA, glucagone-like peptide-1 receptor agonists; FGF, fibroblast growth factor; FXR, farnesoid X receptor; NASH, nonalcoholic steatohepatitis; PPAR, peroxisome proliferator-activated receptor; SCD, stearoyl coenzyme A desaturase; SGLT, sodium-glucose cotransporter; THR, thyroid hormone receptor.
OCA, a farnesoid X receptor agonist, has been demonstrated to reduce hepatic fibrosis without worsening NASH in the 18-month interim analysis of the REGENERATE phase 3 trial [3], and its anti-fibrotic effect and long-term favorable safety profile have recently been validated [4]. However, in May 2023, the FDA rejected the new drug application of OCA for precirrhotic NASH, concerning safety issues such as hepatotoxicity, cholelithiasis, and pruritus, while its efficacy is modest. Resmetirom is a liver-targeted, thyroid hormone receptor β(THR-β)-selective agonist. Based on the promising results in the phase 2 clinical trial [5], phase 3 trials evaluating the efficacy of resmetirom in patients with NASH presenting with compensated cirrhosis (MAESTRO-NASH-Outcomes trial) and stage 2–3 fibrosis (MAESTRO-NASH) are ongoing. In the interim analysis of MAESTRO-NASH trial, which included 955 patients, histological NASH resolution and fibrosis reduction end points were achieved after 52 weeks of treatment [6]. Until now resmetirom is the only drug showing both NASH and fibrosis improvement in a phase 3 trial. The antidiabetic drugs, such as glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and glucose-dependent insulinotropic polypeptide (GIP), are attractive candidates for the treatment of NASH, considering their beneficial metabolic effects. These are incretins that stimulate insulin secretion from pancreatic β cells in response to food ingestion. Semaglutide, a GLP-1 RA, showed a significant dose-dependent NASH resolution without worsening of fibrosis in a phase 2 randomized controlled trial (RCT) involving patients with NASH and stage 1–3 fibrosis [7]. A phase 3 trial of semaglutide for NASH-related fibrosis (ESSENCE trial) is currently underway. However, in a recent phase 2 RCT for NASH-related cirrhosis, semaglutide did not improve fibrosis or NASH resolution, although it showed improvements in cardiometabolic parameters [8]. Effective drug therapy for NASH-related cirrhosis is challenging, as belafectin [9], selonsertib [1], and OCA also failed in this field. Tirzepatide, a dual agonist for GIP and GLP-1 receptors recently approved for type 2 diabetes mellitus, has been shown to reduce hepatic fat content as well as weight loss, suggesting a potential benefit for NASH [10,11]. Additionally, cotadutide, a dual receptor agonist of GLP-1/glucagon [12], and efocipegtrutide, a novel GLP-1/GIP/glucagon triple-receptor co-agonist [13,14], have shown potential as a treatment for NASH. Since glucagon receptors, unlike GIP and GLP-1, are highly expressed in the liver, glucagon agonism has significant impact on metabolism in the liver and extrahepatic tissues [15]. Another antidiabetic drug, dapagliflozin, a sodium-glucose cotransporter-2 inhibitor, has been shown to reduce liver steatosis and fibrosis in small RCTs and meta-analysis [16,17]. A phase 3 trial (DEAN trial) to assess the efficacy and safety of dapagliflozin in improving NASH and metabolic risk factors is still ongoing. A phase 3 trial of aramchol (AMOR trial) was initiated on the basis of the observed safety and changes in liver histology in the phase 2b trial [18]. After the open-label part of the AMOR trial has met its objective, the manufacturer changed its proposed clinical studies with aramchol meglumine instead of aramchol free acid. Accordingly, initiation of the double-blind part is being suspended upon the manufacturer’s strategy. In a phase 2b clinical trial of lanifibranor in patients with NASH and significant fibrosis, lanifibranor achieved both endpoints of NASH resolution and fibrosis improvement, together with an improvement in lipid profile and insulin resistance [19]. A phase 3 trial of lanifibranor in patients with NASH and stage 2–3 fibrosis (NATiV3 trial) is currently ongoing. FGF21 is a non-mitogenic hormone that regulates glucose and lipid metabolism and modulates adiponectin secretion. Recently, pegbelfermin has failed to demonstrate significant reductions in liver fibrosis in patients with NASH [20,21]. In contrast, pegozafermin, a long-acting glycopegylated recombinant FGF21 analogue, led to significant improvements in fibrosis and NASH resolution in patients with stage 2–3 fibrosis (ENLIVEN trial) [22]. These promising results provide the basis for the advancement of pegozafermin into phase 3 development. An update on current pharmacological therapies for non-alcoholic fatty liver disease is summarized in Figure.
Several agents, including THR-ß-selective agonist, antidiabetic drugs, and FGF21 agonists show promise as new therapeutics for NASH, and their efficacy in improving both inflammation and fibrosis, with a long-term safety profile, is expected. Considering the heterogeneity of the disease and the various treatment responses observed in clinical trials for individual drugs, it is challenging to define effective drugs for all patients with NASH [23]. Accordingly, combination treatment or personalized treatment approaches may provide a higher response in the context of disease mechanisms.
Acknowledgments
This work was supported by the Soonchunhyang University Research Fund and the National Research Foundation of Korea (NRF) grant funded by the Korea government (2021R1I1A3059993, RS-2023-00251607).
Abbreviations
- CYP
cytochrome P
- FAO
fatty acid oxidation
- FGF
fibroblast growth factor
- FGFR
fibrosis growth factor receptor
- FXR
farnesoid X receptor
- GLP-1 RA
glucagonelike peptide-1 receptor agonists
- GIP
glucose-dependent insulinotropic polypeptide
- PPAR
peroxisome proliferator-activated receptor
- MPC
mitochondrial pyruvate carrier
- SCD
stearoyl coenzyme A desaturase
- SGLT2
sodium glucose co-transporter 2
- TCA cycle
tricarboxylic acid cycle
- TG
triglyceride
- THR
thyroid hormone receptor
- FDA
US Food and Drug Administration
- NASH
non-alcoholic steatohepatitis
- OCA
obeticholic acid
- RCT
randomized controlled trial
Footnotes
Authors’ contribution
Young Chang drafted and revised the manuscript. Soung Won Jeong designed the concept and revised the manuscript. Jae Young Jang conducted the literature search and reviewed the manuscript.
Conflicts of Interest
The authors have no conflicts to disclose.
REFERENCES
- 1.Harrison SA, Wong VW, Okanoue T, Bzowej N, Vuppalanchi R, Younes Z, et al. Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials. J Hepatol. 2020;73:26–39. doi: 10.1016/j.jhep.2020.02.027. [DOI] [PubMed] [Google Scholar]
- 2.Anstee QM, Neuschwander-Tetri BA, Wai-Sun Wong V, Abdelmalek MF, Rodriguez-Araujo G, Landgren H, et al. Cenicriviroc lacked efficacy to treat liver fibrosis in nonalcoholic steatohepatitis: AURORA Phase III Randomized Study. Clin Gastroenterol Hepatol. doi: 10.1016/j.cgh.2023.04.003. 2023 Apr 13. doi: 10.1016/j.cgh.2023.04.003. [DOI] [PubMed] [Google Scholar]
- 3.Younossi ZM, Ratziu V, Loomba R, Rinella M, Anstee QM, Goodman Z, et al. Obeticholic acid for the treatment of nonalcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial. Lancet. 2019;394:2184–2196. doi: 10.1016/S0140-6736(19)33041-7. [DOI] [PubMed] [Google Scholar]
- 4.Sanyal AJ, Ratziu V, Loomba R, Anstee QM, Kowdley KV, Rinella ME, et al. Results from a new efficacy and safety analysis of the REGENERATE trial of obeticholic acid for treatment of precirrhotic fibrosis due to non-alcoholic steatohepatitis. J Hepatol. doi: 10.1016/j.jhep.2023.07.014. 2023 Jul 28. doi: 10.1016/j.jhep.2023.07.014. [DOI] [PubMed] [Google Scholar]
- 5.Harrison SA, Bashir MR, Guy CD, Zhou R, Moylan CA, Frias JP, et al. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet. 2019;394:2012–2024. doi: 10.1016/S0140-6736(19)32517-6. [DOI] [PubMed] [Google Scholar]
- 6.Harrison S, Bedossa P, Guy C, Schattenberg J, Loomba R, Taub R, et al. Primary results from MAESTRO-NASH a pivotal phase 3 52-week serial liver biopsy study in 966 patients with NASH and fibrosis. J Hepatol. 2023;78:S1. [Google Scholar]
- 7.Newsome PN, Buchholtz K, Cusi K, Linder M, Okanoue T, Ratziu V, et al. A placebo-controlled trial of subcutaneous semaglutide in nonalcoholic steatohepatitis. N Engl J Med. 2021;384:1113–1124. doi: 10.1056/NEJMoa2028395. [DOI] [PubMed] [Google Scholar]
- 8.Loomba R, Abdelmalek MF, Armstrong MJ, Jara M, Kjær MS, Krarup N, et al. Semaglutide 2·4 mg once weekly in patients with non-alcoholic steatohepatitis-related cirrhosis: a randomised, placebo-controlled phase 2 trial. Lancet Gastroenterol Hepatol. 2023;8:511–522. doi: 10.1016/S2468-1253(23)00068-7. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Chalasani N, Abdelmalek MF, Garcia-Tsao G, Vuppalanchi R, Alkhouri N, Rinella M, et al. Effects of belapectin, an inhibitor of galectin-3, in patients with nonalcoholic steatohepatitis with cirrhosis and portal hypertension. Gastroenterology. 2020;158:1334–1345. doi: 10.1053/j.gastro.2019.11.296. e5. [DOI] [PubMed] [Google Scholar]
- 10.Jastreboff AM, Aronne LJ, Ahmad NN, Wharton S, Connery L, Alves B, et al. Tirzepatide once weekly for the treatment of obesity. N Engl J Med. 2022;387:205–216. doi: 10.1056/NEJMoa2206038. [DOI] [PubMed] [Google Scholar]
- 11.Gastaldelli A, Cusi K, Fernández Landó L, Bray R, Brouwers B, Rodríguez Á. Effect of tirzepatide versus insulin degludec on liver fat content and abdominal adipose tissue in people with type 2 diabetes (SURPASS-3 MRI): a substudy of the randomised, open-label, parallel-group, phase 3 SURPASS-3 trial. Lancet Diabetes Endocrinol. 2022;10:393–406. doi: 10.1016/S2213-8587(22)00070-5. [DOI] [PubMed] [Google Scholar]
- 12.Robertson D, Challis B, Daniels SJ, Sarv J, Sanchez J, Schumi J, et al. PROXYMO demonstrates safety and efficacy of cotadutide, a novel incretin co-agonist in biopsy-proven non-cirrhotic NASH with fibrosis. Oral abstract. Hepatology. 2021;74:1383A. [Google Scholar]
- 13.Choi J, Kim JK, Lee SM, Kwon H, Lee J, Bae S, et al. Therapeutic effect of a novel long-acting GLP-1/GIP/Glucagon Triple Agonist (HM15211) in CDHFD-induced NASH and fibrosis mice. Diabetes. 2020;69(Suppl 1):1830–P. [Google Scholar]
- 14.Abdelmalek M, Choi J, Kim Y, Seo K, Hompesch M, Baek S. HM15211, a novel GLP-1/GIP/Glucagon triple-receptor coagonist significantly reduces liver fat and body weight in obese subjects with non-alcoholic fatty liver disease: A Phase 1b/2a, multi-center, randomized, placebo-controlled trial. J Hepatol. 2020;73:S124. [Google Scholar]
- 15.Tilg H, Byrne CD, Targher G. NASH drug treatment development: challenges and lessons. Lancet Gastroenterol Hepatol. 2023;8:943–954. doi: 10.1016/S2468-1253(23)00159-0. [DOI] [PubMed] [Google Scholar]
- 16.Sun L, Deng C, Gu Y, He Y, Yang L, Shi J. Effects of dapagliflozin in patients with nonalcoholic fatty liver disease: A systematic review and meta-analysis of randomized controlled trials. Clin Res Hepatol Gastroenterol. 2022;46:101876. doi: 10.1016/j.clinre.2022.101876. [DOI] [PubMed] [Google Scholar]
- 17.Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T, et al. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21:285–292. doi: 10.1111/dom.13520. [DOI] [PubMed] [Google Scholar]
- 18.Ratziu V, de Guevara L, Safadi R, Poordad F, Fuster F, Flores-Figueroa J, et al. Aramchol in patients with nonalcoholic steatohepatitis: a randomized, double-blind, placebo-controlled phase 2b trial. Nat Med. 2021;27:1825–1835. doi: 10.1038/s41591-021-01495-3. [DOI] [PubMed] [Google Scholar]
- 19.Francque SM, Bedossa P, Ratziu V, Anstee QM, Bugianesi E, Sanyal AJ, et al. A randomized, controlled trial of the Pan-PPAR agonist lanifibranor in NASH. N Engl J Med. 2021;385:1547–1558. doi: 10.1056/NEJMoa2036205. [DOI] [PubMed] [Google Scholar]
- 20.Loomba R, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Harrison SA, et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and stage 3 fibrosis (FALCON 1): A randomized phase 2b study. Clin Gastroenterol Hepatol. 2023 doi: 10.1016/j.cgh.2023.04.011. doi: 10.1016/j.cgh.2023.04.011. [DOI] [PubMed] [Google Scholar]
- 21.Abdelmalek MF, Sanyal AJ, Nakajima A, Neuschwander-Tetri BA, Goodman ZD, Harrison SA, et al. Pegbelfermin in patients with nonalcoholic steatohepatitis and compensated cirrhosis (FALCON 2): A randomized phase 2b study. Clin Gastroenterol Hepatol. 2023 doi: 10.1016/j.cgh.2023.04.012. doi: 10.1016/j.cgh.2023.04.012. [DOI] [PubMed] [Google Scholar]
- 22.Loomba R, Sanyal AJ, Kowdley KV, Bhatt DL, Alkhouri N, Frias JP, et al. Randomized, controlled trial of the FGF21 analogue pegozafermin in NASH. N Engl J Med. 2023;389:998–1008. doi: 10.1056/NEJMoa2304286. [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.An J, Sohn JH. Pharmacological advances in the treatment of nonalcoholic fatty liver diseases: focused on global results of randomized controlled trials. Clin Mol Hepatol. 2023;29(Suppl):S268–S275. doi: 10.3350/cmh.2022.0437. [DOI] [PMC free article] [PubMed] [Google Scholar]